Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 4/20 | 0.43 |
| ▸ | TTK | P33981 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | BPTF | Q12830 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619120 | 0.85 | SCN9A (0.46) | SCN9ATTKHTR6BPTFEGFR | |
| SCHEMBL5618073 | 0.79 | FLT3 (0.49) | FLT3TTKBPTFEGFR | |
| SCHEMBL5401140 | 0.73 | FLT3 (0.55) | FLT3TTKAURKAAURKB | |
| SCHEMBL14573304 | 0.73 | NR4A1 (0.42) | FLT3TTK | |
| SCHEMBL6366899 | 0.72 | TTK (0.45) | FLT3TTKAURKAAURKB | |
| SCHEMBL5618106 | 0.70 | TTK (0.56) | FLT3TTKAURKA | |
| SCHEMBL5618954 | 0.70 | FLT3 (0.51) | FLT3TTKEED | |
| SCHEMBL5413864 | 0.70 | KDM4E (0.55) | FLT3TTKAURKAAURKB | |
| SCHEMBL5406217 | 0.70 | FLT3 (0.53) | FLT3TTKAURKAAURKB | |
| SCHEMBL5617891 | 0.69 | FLT3 (0.52) | FLT3TTKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | SCN9A 2257/4885FLT3 216/4885TTK 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.